과제정보
This research was supported by a grant (14172MFDS178) from the Ministry of Food and Drug Safety in 2014.
참고문헌
- Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) 2012;2:209-17. https://doi.org/10.1038/kisup.2012.23
- Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000;20:373-9. https://doi.org/10.1159/000013619
- Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, et al. Effect of lowdose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J Intern Med 2016;31:335-4.
- Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 2009;24:845-9. https://doi.org/10.1007/s00467-008-1006-8
- Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis 2015;66:783-91. https://doi.org/10.1053/j.ajkd.2015.06.013
- Masutani K, Tsuchimoto A, Yamada T, Hirakawa M, Mitsuiki K, Katafuchi R, et al. Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial. Clin Exp Nephrol 2016;20:896-903. https://doi.org/10.1007/s10157-016-1226-3
- Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2015;(8):CD003965.
- Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 2012;27:1479-85. https://doi.org/10.1093/ndt/gfr527
- Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011;22:752-61. https://doi.org/10.1681/ASN.2010040355
- Graciano ML, Cavaglieri Rde C, Delle H, Dominguez WV, Casarini DE, Malheiros DM, et al. Intrarenal renin-angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol 2004;15:1805-15. https://doi.org/10.1097/01.ASN.0000131528.00773.A9
- Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. https://doi.org/10.1056/NEJMoa011161
- Xie Y, Huang S, Wang L, Miao L, Zhang A, Li Y, et al. Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study. Am J Med Sci 2011;341:367-72. https://doi.org/10.1097/MAJ.0b013e318207e02d
- Horita Y, Tadokoro M, Taura K, Ashida R, Hiu M, Taguchi T, et al. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 2007;29:441-6. https://doi.org/10.1080/08860220701260511
- Shimizu A, Takei T, Uchida K, Tsuchiya K, Nitta K. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res 2008;31:1711-7. https://doi.org/10.1291/hypres.31.1711
- Chandar J, Abitbol C, Montane B, Zilleruelo G. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 2007;22:1332-7. https://doi.org/10.1093/ndt/gfl839
- Mahmoudpour SH, Veluchamy A, Siddiqui MK, Asselbergs FW, Souverein PC, de Keyser CE, et al. Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. Pharmacogenet Genomics 2017;27:112-9. https://doi.org/10.1097/FPC.0000000000000264
- Webb NJ, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, et al. Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol 2010;5:417-24. https://doi.org/10.2215/CJN.06620909
- Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan: a long-term study in children with renal disorders. Am J Hypertens 2004;17:928-35. https://doi.org/10.1016/S0895-7061(04)00875-1
- Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H, et al. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol 2019;34:837-46. https://doi.org/10.1007/s00467-018-4099-8
- Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 2012;82:819-26. https://doi.org/10.1038/ki.2012.210
- Litwin M, Grenda R, Sladowska J, Antoniewicz J. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 2006;21:1716-22. https://doi.org/10.1007/s00467-006-0223-2
- D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992;20:315-23. https://doi.org/10.1016/S0272-6386(12)70293-7
- Kusumoto Y, Takebayashi S, Taguchi T, Harada T, Naito S. Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol 1987;28:118-24.
- Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol 2015;30:2121-7. https://doi.org/10.1007/s00467-015-3176-5
- Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol 2005;64:171-9. https://doi.org/10.5414/CNP64171
- Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant 2008;23:2537-45. https://doi.org/10.1093/ndt/gfn014
- Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 2013;28:71-6. https://doi.org/10.1007/s00467-012-2294-6
- Suh JS, Jang KM, Hyun H, Cho MH, Lee JH, Park YS, et al. Remission of proteinuria may protect against progression to chronic kidney disease in pediatric-onset IgA nephropathy. J Clin Med 2020;9:2058.
- Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005;18(2 Pt 1):183-90. https://doi.org/10.1016/j.amjhyper.2004.09.009
- Wuhl E, Mehls O, Schaefer F; ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 2004;66:768-76. https://doi.org/10.1111/j.1523-1755.2004.00802.x
- Sakalli H, Baskin E, Bayrakci US, Moray G, Haberal M. Acidosis and hyperkalemia caused by losartan and enalapril in pediatric kidney transplant recipients. Exp Clin Transplant 2014;12:310-3.
- Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al. A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol 2014;9:1441-8. https://doi.org/10.2215/CJN.11111113